For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
VIEWPOINT: Learning to live with COVID-19 makes no sense for New Zealand
+News
VIEWPOINT
VIEWPOINT: Learning to live with COVID-19 makes no sense for New Zealand
Friday 21 August 2020, 11:52 AM
![Forest fire [Sippakorn Yamkasikorn on Unsplash]](/sites/default/files/styles/cropped_image_16_7_/public/2020-08/sippakorn-yamkasikorn-nVYEechGqqM-unsplash.jpg?itok=4yMAkw2t)
Think of a person infected by COVID-19 as being like a spark that has jumped out of a fire - the consequences depend on where that spark lands [Sippakorn Yamkasikorn on Unsplash]
Auckland University epidemiologist Rod Jackson explains the figures on elimination, Sweden and why herd immunity is not a goer
What the epidemiological evidence informs us is that within one month of infection with COVID-19, you will either be dead or no longer infectious
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.